We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00414349
Previous Study | Return to List | Next Study

Efficacy and Safety of Topical Versus Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00414349
Recruitment Status : Completed
First Posted : December 21, 2006
Last Update Posted : October 9, 2019
Information provided by (Responsible Party):
Grünenthal GmbH

Brief Summary:
The purpose of this study is to evaluate lidocaine as topical treatment for peripheral neuropathic pain (as stand-alone treatment and in combination with systemic treatment)

Condition or disease Intervention/treatment Phase
Neuropathic Pain Drug: Topical analgesic Drug: oral intake Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 431 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Lidocaine 5% Medicated Plaster in Comparison to Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain.
Study Start Date : December 2006
Actual Primary Completion Date : January 2008
Actual Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shingles

Arm Intervention/treatment
Experimental: 1 Drug: Topical analgesic
max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients

Active Comparator: 2 Drug: oral intake
300 to 600 mg per day taken orally

Experimental: 3 Drug: Topical analgesic
3 plasters for PHN patients per day 4 plasters for DPN patients per day

Primary Outcome Measures :
  1. Reduction of pain expressed by response rate after 4 weeks treatment every 4 weeks of single or combination treatment: change in neuropathic pain, change in quality of life, change in sleep quality [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects with >= 18 years of age
  • Intact skin in the area of topical treatment
  • Creatinine clearance CLCR >= 30 mL/min
  • NRS-3 > 4 (recalled average pain intensity during the last 3 days)

Subjects with DPN

  • Controlled, treated type 1 or 2 diabetes mellitus with glycosylated hemoglobin (Hba1c)<= 11%
  • Painful, distal symmetrical, sensomotor polyneuropathy of the lower extremities for >= 3 months (below the knees on both extremities) with at least 2 of the following symptoms present: burning, sensation, tingling or prickling, numbness from time to time, painful heat or cold sensation (e.g. warm or cold water)

Subjects with PHN

  • Subjects with PHN and neuropathic pain present for >= 3 months after healing of the herpes zoster skin rash.
  • Without neurolytic neurosurgical therapy for their condition.

Exclusion Criteria:


  • Evidence or history of alcohol, medication or drug abuse and/or dependency in the past 2 years, unstable psychological personality requiring intermittent or permanent treatment.
  • Psychiatric illness (subjects with well-controlled depression or anxiety disorder may participate if they are not taking any of the prohibited medications defined (below), epilepsy or suicide risk.
  • Pregnant or breastfeeding women
  • Women of childbearing potential who are sexually active without satisfactory contraception for at least 28 days prior to enrollment, during the trial, and until 28 days after the follow-up visit.
  • Subjects with severe cardiac impairment e.g. NYHA class > 3, myocardial infarction less than 6 months prior to enrollment, and/or unstable angina pectoris.
  • Subjects with severe hepatic disorder and/or AST or ALT >= 3x the upper limit of normal.
  • Subjects with known or suspected severe renal failure (CLCR < 30 mL/min).
  • Anticipated need for surgery during the trial, requiring at least regional or general anesthesia.
  • Subjects who are undergoing active treatment for cancer, are known to be infected with HIV or being acutely and intensively immunosuppressed following transplantation.
  • Participation in another trial of investigational medicinal products or devices parallel to or less than 1 month before entry into the trial, or previous participation in this trial.

Trial specific:

  • Any concomitant use of drugs for the treatment of neuropathic pain or commonly used for the treatment of neuropathic pain.
  • Use of transcutaneous electrical nerve stimulations (TENS) after enrollment.
  • CLCR < 30 mL/min
  • Evidence of another cause for pain in the area of neuropathic pain such as lumbar radiculopathy, surgery trauma, restless legs syndrome, if this coud confound the assessment or self-evaluation of the neuropathic pain.
  • Presence of other severe pain that could confound the assessment or self-evaluation of the neuropathic pain.
  • History of malignancy within the past 5 years (with the exception of basal cell carcinoma).

Subjects with PHN

  • Active herpes zoster lesion or dermatitis of any origin at the affected site with PHN.
  • Subjects who had neurological ablation by block or neurosurgical intervention for control of pain in PHN.

Subjects with DPN

  • No palpable pulse of the arteria dorsalis pedis in both feet.
  • Clinical signs for venous insufficiency and/or postthrombotic syndrome Sage III/IV (i.e. extensive varicoses)
  • Ulcers on the lower extremities.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00414349

Layout table for location information
United Kingdom
London, United Kingdom
Sponsors and Collaborators
Grünenthal GmbH
Layout table for investigator information
Principal Investigator: Ralf Baron, Prof. Dr. Klinik für Neurologie, Christian-Albrechts-Universität Kiel, Schittenhelmstr. 10, 24105 Kiel, Germany
Publications of Results:
Layout table for additonal information
Responsible Party: Grünenthal GmbH
ClinicalTrials.gov Identifier: NCT00414349    
Other Study ID Numbers: 796838
KF10004/03 ( Other Identifier: Sponsor study number )
First Posted: December 21, 2006    Key Record Dates
Last Update Posted: October 9, 2019
Last Verified: October 2019
Keywords provided by Grünenthal GmbH:
Topical analgesic
Multiple dose
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuralgia, Postherpetic
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Neurologic Manifestations
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs